Clinical Trials Logo

Filter by:
NCT ID: NCT04557553 Completed - Osteoporosis Clinical Trials

Effects of Lagenbone on Bone Mineral Density

Start date: July 15, 2019
Phase: N/A
Study type: Interventional

To study the effects of the herbal supplement Lagenbone on Bone Mineral Density

NCT ID: NCT04557540 Completed - Clinical trials for Obesity-Related Malignant Neoplasm

Weight Loss Interventions for Black Adults of Faith

Start date: September 25, 2021
Phase: N/A
Study type: Interventional

This trial compares the effect of intermittent fasting versus continuous caloric reduction for the reduction of body weight in Black adults of faith. Intermittent fasting and continuous caloric reduction interventions may help Black adults of faith lose weight, improve their health, and help reduce cancer risk.

NCT ID: NCT04557410 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Open Label Study: Treatment of ALS Fatigue With PolyMVA

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

Amyotrophic lateral sclerosis (ALS) is a disease that causes the death of upper and lower motor neurons. ALS symptoms are characterized by stiffness, muscle twitching, and worsening weakness due to muscle breakdown. Onset of symptoms are typically arm or leg weakness or difficulty speaking or swallowing and gradual development of overall body weakness. The cause is unknown and there is no cure for ALS. Poly MVA was found to substantially lower fatigue and improve quality of life in a pilot study of patients with varied medical disorders. The reduction in fatigue was also observed in a small series of patients enrolled in an open label study for patients with gliomas. In this study, we want to find out more about a dietary supplement, called Poly MVA (also called the study drug in this form), for people with ALS. We want to find out if Poly MVA reduces the symptoms of fatigue and depression when taken daily. The supplement contains vitamins, minerals and amino acids (proteins) and has been used by patients with other medical conditions to help with their fatigue and quality of life.

NCT ID: NCT04557397 Completed - Clinical trials for Drug Drug Interaction

Fruquintinib CYP3A Inhibitor and Inducer Study

Start date: September 2, 2020
Phase: Phase 1
Study type: Interventional

A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.

NCT ID: NCT04557332 Completed - HIV-1-infection Clinical Trials

mHealth for ART Adherence by HIV+ African Americans

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The objective of this grant is to create and test a mobile app to support ART adherence among HIV+ African American adults.

NCT ID: NCT04557280 Completed - Healthy Subjects Clinical Trials

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Start date: November 6, 2020
Phase: Phase 1
Study type: Interventional

The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations. The clinical pharmacology data will be used to support demonstration of bioequivalence and interchangeability of the different formulations.

NCT ID: NCT04557241 Completed - Clinical trials for COVID19 Behavioral Prophylaxis

Brief Informational Intervention for COVID-19 Misinformation Prophylaxis

Start date: January 14, 2020
Phase: N/A
Study type: Interventional

As the coronavirus disease 2019 (COVID-19) pandemic has continued to affect life in the United States, the important role of non-pharmaceutical preventive behaviors (such as wearing a face mask) in reducing harm has become clear. In parallel to the pandemic, researchers have observed an "infodemic" of misinformed or inconsistent narratives about COVID-19. There is growing evidence that misinformed COVID-19 narratives are associated with a wide variety of undesirable behavior (e.g., burning down cell towers). Further, individuals' adherence to recommended COVID-19 preventive guidelines has been inconsistent, and such mandates have engendered opposition and controversy. Recent research suggests the possibility that trust in science and scientists may be an important thread to weave throughout these seemingly disparate components of the modern public health landscape. Thus, this paper describes the protocol for a randomized trial of a brief, digital intervention to increase trust in science. The objective of this trial is to examine if exposure to a curated infographic can increase trust in science, reduce believability of misinformed narratives, and increase likelihood to engage in preventive behaviors.

NCT ID: NCT04557215 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Efficacy and Safety of Rifaximin With NAC in IBS-D

Start date: November 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized, prospective proof of concept, double-blind, single site clinical trial to determine the efficacy of combined rifaximin and N-acetylcysteine (NAC) therapy vs. rifaximin alone in decreasing clinical symptoms in subjects with IBS-D.

NCT ID: NCT04557189 Completed - Clinical trials for Postoperative Nausea and Vomiting (PONV)

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

Some adults are at a higher risk of feeling sick (nausea) or being sick (vomiting) after they have surgery. In this study, these adults will have planned surgery. The main aim of this study is to learn if TAK-951 stops these adults from getting nausea or vomiting after surgery. This will be compared with another medicine called ondansetron. Another aim is to check for side effects from the study medicines. Before surgery, the study doctor will check who can take part in this study. Those who can take part will be picked for either Treatment Group A or Treatment Group B by chance. - Treatment Group A: Just before surgery, participants will receive a placebo slowly through a vein (infusion). Just before the end of the surgery, they will receive TAK-951 as an injection under the skin. - Treatment Group B: Just before surgery, participants will receive ondansetron slowly through a vein (infusion). Just before the end of the surgery, they will receive a placebo as an injection under the skin. In this study, a placebo will look like TAK-951 but will not have any medicine in it. Participants will not know which study medicines they received, or in which order, nor will their study doctors or surgeons. This is to help make sure the results are more reliable. Participants will stay in the hospital for 24 hours after their surgery so that the study doctors can check for nausea and vomiting. The study doctors will also check for side effects from the study medicines. Participants will visit the hospital for a check-up 14 days later.

NCT ID: NCT04557033 Completed - Mindfulness Clinical Trials

My Mindful Moments: A Mindfulness Meditation and Digital Art Activity

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this evidence-based practice project is to evaluate the feasibility of providing a relaxation mindfulness meditation and an expressive digital arts activity among clinical staff at Dana Farber Cancer Institute .